BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects
- Conditions
- First Posted Date
- 2006-11-09
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00397566
Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2012-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 109
- Registration Number
- NCT00395018
- Locations
- 🇺🇸
University Of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Tulane University Hospital & Clinic, New Orleans, Louisiana, United States
🇺🇸Baylor College Of Medicine, Houston, Texas, United States
Bioequivalence Study of Atazanavir 300 mg Capsule
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT00393328
- Locations
- 🇺🇸
Local Institution, Hamilton, New Jersey, United States
A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection
- Conditions
- Interventions
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 122
- Registration Number
- NCT00393484
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 13
- Registration Number
- NCT00390936
- Locations
- 🇯🇵
Local Institution, Sunto-Gun, Shizuoka, Japan
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 34
- Registration Number
- NCT00389155
- Locations
- 🇺🇸
Medical College Of Georgia, Augusta, Georgia, United States
🇺🇸Nevada Cancer Centers, Las Vegas, Nevada, United States
🇺🇸Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona, United States
Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 705
- Registration Number
- NCT00388609
- Locations
- 🇺🇸
Domenica M. Rubino, Md, Washington, District of Columbia, United States
🇺🇸Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
🇺🇸Springfield Diabetes And Endocrine Center, Springfield, Illinois, United States
Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12522
- Registration Number
- NCT00388674
- Locations
- 🇺🇸
Office Of Sing Chan Md, Flushing, New York, United States
🇺🇸Orlando Immunology Center, Orlando, Florida, United States
🇺🇸Scti Research Foundation, Coronado, California, United States
Effect of Ketoconazole on the Pharmacokinetics of Vinflunine
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT00388557
- Locations
- 🇺🇸
Tennessee Oncology, Pllc, Nashville, Tennessee, United States
Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
- First Posted Date
- 2006-10-09
- Last Posted Date
- 2013-04-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 94
- Registration Number
- NCT00385580
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸The Bunting Blaustein Cancer Research Building, Baltimore, Maryland, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States